Research Paper Volume 13, Issue 3 pp 3536—3553

Identification of HIPK3 as a potential biomarker and an inhibitor of clear cell renal cell carcinoma

Diagnostic efficiency of HIPK3 in ccRCC. (A) ROC curve of HIPK3 between tumor and non-cancerous normal tissues, the AUC: HIPK3, 0.8144 (pB) ROC curve of HIPK3 between tumor and paired non-cancerous normal tissues, the AUC: 0.7567, (pC) Living vs deceased, AUC:0.6397, (pD) Recurred vs disease free, AUC:0.6128, (pE) M1 / M0 stage, AUC = 0.5929, (p=0.008). (F) (T3 + T4) / (T1 + T2), AUC = 0.5750, (p=0.004). (G) Pathological stage (III + IV)/ (I + II), AUC = 0.6012, (p

Figure 6. Diagnostic efficiency of HIPK3 in ccRCC. (A) ROC curve of HIPK3 between tumor and non-cancerous normal tissues, the AUC: HIPK3, 0.8144 (p<0.0001); (B) ROC curve of HIPK3 between tumor and paired non-cancerous normal tissues, the AUC: 0.7567, (p<0.0001); (C) Living vs deceased, AUC:0.6397, (p<0.0001); (D) Recurred vs disease free, AUC:0.6128, (p<0.0001). (E) M1 / M0 stage, AUC = 0.5929, (p=0.008). (F) (T3 + T4) / (T1 + T2), AUC = 0.5750, (p=0.004). (G) Pathological stage (III + IV)/ (I + II), AUC = 0.6012, (p < 0.0001). HIPK, Homeodomain interacting protein kinases; AUC, Area under the curve; ROC receiver operator characteristic.